GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bruker Corp (NAS:BRKR) » Definitions » ROE %

Bruker (Bruker) ROE %

: 63.57% (As of Dec. 2023)
View and export this data going back to 2000. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Bruker's annualized net income for the quarter that ended in Dec. 2023 was $822 Mil. Bruker's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $1,293 Mil. Therefore, Bruker's annualized ROE % for the quarter that ended in Dec. 2023 was 63.57%.

The historical rank and industry rank for Bruker's ROE % or its related term are showing as below:

BRKR' s ROE % Range Over the Past 10 Years
Min: 7.03   Med: 21.81   Max: 34.95
Current: 34.95

During the past 13 years, Bruker's highest ROE % was 34.95%. The lowest was 7.03%. And the median was 21.81%.

BRKR's ROE % is ranked better than
97.17% of 812 companies
in the Medical Devices & Instruments industry
Industry Median: 0.27 vs BRKR: 34.95

Bruker ROE % Historical Data

The historical data trend for Bruker's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bruker Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.87 16.90 27.28 27.16 34.30

Bruker Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.99 26.68 18.94 28.89 63.57

Competitive Comparison

For the Medical Devices subindustry, Bruker's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bruker ROE % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Bruker's ROE % distribution charts can be found below:

* The bar in red indicates where Bruker's ROE % falls into.



Bruker ROE % Calculation

Bruker's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=427.2/( (1113.8+1377.2)/ 2 )
=427.2/1245.5
=34.30 %

Bruker's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=822/( (1208.8+1377.2)/ 2 )
=822/1293
=63.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Bruker  (NAS:BRKR) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=822/1293
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(822 / 3418)*(3418 / 4034.75)*(4034.75 / 1293)
=Net Margin %*Asset Turnover*Equity Multiplier
=24.05 %*0.8471*3.1205
=ROA %*Equity Multiplier
=20.37 %*3.1205
=63.57 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=822/1293
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (822 / 963.6) * (963.6 / 533.2) * (533.2 / 3418) * (3418 / 4034.75) * (4034.75 / 1293)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8531 * 1.8072 * 15.6 % * 0.8471 * 3.1205
=63.57 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Bruker ROE % Related Terms

Thank you for viewing the detailed overview of Bruker's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bruker (Bruker) Business Description

Traded in Other Exchanges
Address
40 Manning Road, Billerica, MA, USA, 01821
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives a majority of its revenue from Europe.
Executives
Frank H Laukien director, 10 percent owner, officer: CEO, President C/O BRUKER DALTONICS, 40 MANNING ROAD, BILLERICA MA 01821
Marc A Kastner director BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Cynthia M Friend director C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Richard A Packer director 9 KENDALL DRIVE, WESTBOROUGH MA 01581
Philip Ma director C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Mark Munch officer: Pres. Bruker Nano Inc. BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Juergen Srega officer: Group President Bruker CALID BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Burkhard Prause officer: Pres. & CEO, Bruker EST BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Bonnie H Anderson director 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Martin Gilles Gerard Jean director BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Falko Busse officer: President, BioSpin Group 40 MANNING ROAD, BILLERICA MA 01821
Gerald N Herman officer: Vice President, Corp Contr. 55 EXECUTIVE DRIVE, HUDSON NH 03051
Ingen Chris Van director 395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Richard Kniss director 395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Adelene Q Perkins director C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139